Show simple item record

dc.contributor.authorBonifacio, E
dc.contributor.authorMathieu, C
dc.contributor.authorNepom, GT
dc.contributor.authorZiegler, A-G
dc.contributor.authorAnhalt, H
dc.contributor.authorHaller, MJ
dc.contributor.authorHarrison, LC
dc.contributor.authorHebrok, M
dc.contributor.authorKushner, JA
dc.contributor.authorNorris, JM
dc.contributor.authorPeakman, M
dc.contributor.authorPowers, AC
dc.contributor.authorTodd, JA
dc.contributor.authorAtkinson, MA
dc.date.accessioned2021-02-04T00:58:30Z
dc.date.available2021-02-04T00:58:30Z
dc.date.issued2017-01-01
dc.identifierpii: 10.1007/s00125-016-4144-8
dc.identifier.citationBonifacio, E., Mathieu, C., Nepom, G. T., Ziegler, A. -G., Anhalt, H., Haller, M. J., Harrison, L. C., Hebrok, M., Kushner, J. A., Norris, J. M., Peakman, M., Powers, A. C., Todd, J. A. & Atkinson, M. A. (2017). Rebranding asymptomatic type 1 diabetes: the case for autoimmune beta cell disorder as a pathological and diagnostic entity. DIABETOLOGIA, 60 (1), pp.35-38. https://doi.org/10.1007/s00125-016-4144-8.
dc.identifier.issn0012-186X
dc.identifier.urihttp://hdl.handle.net/11343/259238
dc.description.abstractThe asymptomatic phase of type 1 diabetes is recognised by the presence of beta cell autoantibodies in the absence of hyperglycaemia. We propose that an accurate description of this stage is provided by the name 'Autoimmune Beta Cell Disorder' (ABCD). Specifically, we suggest that this nomenclature and diagnosis will, in a proactive manner, shift the paradigm towards type 1 diabetes being first and foremost an immune-mediated disease and only later a metabolic disease, presaging more active therapeutic intervention in the asymptomatic stage of disease, before end-stage beta cell failure. Furthermore, we argue that accepting ABCD as a diagnosis will be critical in order to accelerate pharmaceutical, academic and public activities leading to clinical trials that could reverse beta cell autoimmunity and halt progression to symptomatic insulin-requiring type 1 diabetes. We recognize that there are both opportunities and challenges in the implementation of the ABCD concept but hope that the notion of 'asymptomatic autoimmune disease' as a disorder will be widely discussed and eventually accepted.
dc.languageEnglish
dc.publisherSPRINGER
dc.rights.urihttps://creativecommons.org/licenses/by/4.0
dc.titleRebranding asymptomatic type 1 diabetes: the case for autoimmune beta cell disorder as a pathological and diagnostic entity
dc.typeJournal Article
dc.identifier.doi10.1007/s00125-016-4144-8
melbourne.affiliation.departmentMedical Biology (W.E.H.I.)
melbourne.affiliation.facultyMedicine, Dentistry & Health Sciences
melbourne.source.titleDiabetologia
melbourne.source.volume60
melbourne.source.issue1
melbourne.source.pages35-38
dc.rights.licenseCC BY
melbourne.elementsid1208937
melbourne.contributor.authorHarrison, Leonard
dc.identifier.eissn1432-0428
melbourne.accessrightsOpen Access


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record